- 1.
Wilhelm H, Schabet M. The diagnosis and treatment of optic neuritis. Dtsch Arztebl Int 2015; 112: 616–25, quiz 626. [PubMed]
- 2.
Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65: 727–32. [PubMed]
- 3.
Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014; 13: 83–99. [PubMed][CrossRef]
- 4.
Bruscolini A, Sacchetti M, La Cava M et al. Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmun Rev 2018; 17: 195–200. [PubMed][CrossRef]
- 5.
Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–89. [PubMed][CrossRef]
- 6.
Wynford-Thomas R, Jacob A, Tomassini V. Neurological update: MOG antibody disease. J Neurol 2019; 266: 1280–6. [PubMed][CrossRef]
- 7.
Gaier ED, Boudreault K, Rizzo JF et al. Atypical optic neuritis. Curr Neurol Neurosci Rep 2015; 15: 76. [PubMed][CrossRef]
- 8.
Duignan S, Wright S, Rossor T et al. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 2018; 60: 958–62. [PubMed][CrossRef]
- 9.
Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014; 261: 17–26. [PubMed][CrossRef]
- 10.
Lee HJ, Kim B, Waters P et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation 2018; 15: 302. [PubMed][CrossRef]
- 11.
Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol 2019; 31: 250–5. [PubMed][CrossRef]
- 12.
Bonnan M, Valentino R, Debeugny S et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89: 346–51. [PubMed][CrossRef]
- 13.
Abboud H, Petrak A, Mealy M et al. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22: 185–92. [PubMed][CrossRef]
- 14.
Cabre P, Mejdoubi M, Jeannin S et al. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol 2018; 265: 917–25. [PubMed][CrossRef]
- 15.
Nikoo Z, Badihian S, Shaygannejad V et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264: 2003–9. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.